Ferroptosis-centered Disease Response Information
General Information of the Disease (ID: DIS00025)
Name |
Oesophageal cancer
|
||||
---|---|---|---|---|---|
ICD |
ICD-11: 2B70
|
Full List of Target(s) of This Ferroptosis-centered Disease
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
In total 12 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Esophageal cancer [ICD-11: 2B70] | ||||
Responsed Drug | Oridonin | Investigative | |||
Responsed Regulator | Glutathione hydrolase 1 proenzyme (GGT1) | Suppressor | |||
Pathway Response | Glutathione metabolism | hsa00480 | |||
Fatty acid metabolism | hsa01212 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model | TE-1 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 | |
Response regulation | The levels of intracellular iron, malondialdehyde, and reactive oxygen species after oridonin (Ori) treatment, while interfering with the effects of Ori with ferroptosis inhibitor, demonstrating that Ori's inhibition of TE1( esophageal cancer cell) cell proliferation is associated with ferroptosis. Ori can inhibit the gamma-glutamyl cycle by inhibiting the activity of GGT1 and binding to cysteine, thereby inducing ferroptosis to exert anti-cancer activity. Eventually, the value of intracellular GSH/GSSG was reduced, and the enzymatic activity of the glutathione peroxidase 4 (GPX4) was significantly decreased. | ||||
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Esophageal cancer [ICD-11: 2B70] | ||||
Responsed Drug | Oridonin | Investigative | |||
Responsed Regulator | Glutathione hydrolase 1 proenzyme (GGT1) | Suppressor | |||
Pathway Response | Glutathione metabolism | hsa00480 | |||
Fatty acid metabolism | hsa01212 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model | TE-1 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 | |
Response regulation | The levels of intracellular iron, malondialdehyde, and reactive oxygen species after oridonin (Ori) treatment, while interfering with the effects of Ori with ferroptosis inhibitor, demonstrating that Ori's inhibition of TE1(esophageal cancer cell) cell proliferation is associated with ferroptosis. Ori can inhibit the gamma-glutamyl cycle by inhibiting the activity of GGT1 and binding to cysteine, thereby inducing ferroptosis to exert anti-cancer activity. Eventually, the value of intracellular GSH/GSSG was reduced, and the enzymatic activity of the glutathione peroxidase 4 (GPX4) was significantly decreased. | ||||
Experiment 3 Reporting the Ferroptosis-centered Disease Response by This Target | [4] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70] | ||||
Responsed Drug | 5-aminolevulinic acid | Approved | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model | KYSE30 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1351 | |
KYSE-510 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1354 | ||
MKN45 cells | Gastric adenocarcinoma | Homo sapiens | CVCL_0434 | ||
In Vivo Model |
KYSE30 cells were subcutaneously inoculated with 5 x 106 cells per site into both flanks on day 0. At 1 week after transplantation, tumor-bearing mice were randomly assigned to one of the following three groups: (1) saline as a control, (2) 10 mg/kg/day of 5-ALA, or (3) 30 mg/kg/day of 5-ALA. The treatment groups were orally administered 5-ALA once daily for 4 weeks, and the control group was orally administered saline during the same period.
Click to Show/Hide
|
||||
Response regulation | Modulation of GPX4 and HMOX1 by 5-aminolevulinic acid (5-ALA) induced ferroptosis in esophageal squamous cell carcinoma (ESCC). Furthermore, 5-ALA led to an increase in lipid peroxidation and exerted an antitumor effect in various cancer cell lines, which was inhibited by ferrostatin-1. Thus, 5-ALA could be a promising new therapeutic agent for ESCC. | ||||
Experiment 4 Reporting the Ferroptosis-centered Disease Response by This Target | [5] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70] | ||||
Responsed Regulator | DnaJ homolog subfamily B member 6 (DNAJB6) | Driver | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model | TE-1 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 | |
EC9706 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_E307 | ||
Eca-109 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_6898 | ||
KYSE150 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1348 | ||
KYSE-450 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1353 | ||
In Vivo Model |
Female BALB/c athymic nude mice (4 weeks of age) were obtained from the HFK Bioscience Co, Beijing. To generate murine subcutaneous tumors, 2 x 106 Eca109 cells and KYSE 150 cells in 100 ul PBS were injected subcutaneously on the left of the nude mices dorsal midline. The xenografts were measured every 4 days.
Click to Show/Hide
|
||||
Response regulation | The correlation between DNAJB6 level and lymph node metastasis in esophageal squamous cell carcinoma (ESCC) patient was negative. Overexpressing DNAJB6a shows tumor-suppressive effects in vitro and in vivo. In addition, DNAJB6a overexpression was accompanied together with a remarkable reduction in the protein levels of GPX4 and phosphorylated AKT (p-AKT). | ||||
Experiment 5 Reporting the Ferroptosis-centered Disease Response by This Target | [6] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70] | ||||
Responsed Regulator | Frizzled-3 (FZD3) | Suppressor | |||
Pathway Response | Wnt signaling pathway | hsa04310 | |||
Fatty acid metabolism | hsa01212 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
Cell invasion | |||||
In Vitro Model | EC9706 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_E307 | |
KYSE-70 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1356 | ||
hEECs (Human esophageal epithelial cells) | |||||
In Vivo Model |
BALB/c nude male mice of 4 weeks old were purchased from the Model Animal Research Center of Nanjing University (Nanjing, China). After one week of adaptive feeding, EC9706 cells (3 x 106) stably expressing sh-NC and sh-circPVT1, sh-NC + 5-FU and sh-circPVT1 + 5-FU were subcutaneously were injected into the right flank of the nude mice in a serum-free DMEM medium.
Click to Show/Hide
|
||||
Response regulation | CircPVT1 regulated the chemosensitivity of esophageal squamous cell carcinoma cells through ROS and Wnt/-catenin pathwaysviamiR-30a-5p/FZD3. Knockdown of circPVT1 promoted chemosensitivity in ESCC by increasing ferroptosis via downregulating GPX4 and SLC7A11. | ||||
Experiment 6 Reporting the Ferroptosis-centered Disease Response by This Target | [7] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Esophageal cancer [ICD-11: 2B70] | ||||
Responsed Regulator | Transportin-1 (TNPO1) | Driver | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
Cell migration | |||||
Cell invasion | |||||
In Vitro Model | Eca-109 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_6898 | |
In Vivo Model |
Nude mice of both sexes (age: 6-8 weeks, weight: 22-25 g) were purchased from HUNAN SJA LABRATORY ANIMAL CO., LTD (Hunan, China). The EC109 cells stably expressing sh-circBCAR3 or sh-nc were established by infection with corresponding lentivirus vectors. 1 x 106 mL-1 (100 uL) cells were subcutaneously inoculated into the nude mice. The tumor volumes had been measured from day 5 to day 25. On day 25, the xenograft tumors were removed surgically, and the tumor weight was detected.
Click to Show/Hide
|
||||
Response regulation | CircBCAR3 binds with miR-27a-3p to promote TNPO1 expression. GPX4 protein levels were increased by silencing of circBCAR3. And circBCAR3 promoted the proliferation, migration, invasion, and ferroptosis of esophageal cancer cells by miR-27a-3p. | ||||
Experiment 7 Reporting the Ferroptosis-centered Disease Response by This Target | [8] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70] | ||||
Responsed Regulator | Cysteine--tRNA ligase, cytoplasmic (CARS1) | Driver | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
Cell migration | |||||
Cell invasion | |||||
In Vitro Model | KYSE30 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1351 | |
KYSE-410 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1352 | ||
Response regulation | CARS1 significantly inhibited cell proliferation, and the ability of migration and invasion promoted the relative level of MDA and ROS and decreased GPX4 expression level in two esophageal squamous cell carcinoma(ESCC) cell lines. | ||||
Experiment 8 Reporting the Ferroptosis-centered Disease Response by This Target | [7] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Esophageal cancer [ICD-11: 2B70] | ||||
Responsed Regulator | hsa-miR-27a-3p (miRNA) | Suppressor | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
Cell migration | |||||
Cell invasion | |||||
In Vitro Model | Eca-109 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_6898 | |
In Vivo Model |
Nude mice of both sexes (age: 6-8 weeks, weight: 22-25 g) were purchased from HUNAN SJA LABRATORY ANIMAL CO., LTD (Hunan, China). The EC109 cells stably expressing sh-circBCAR3 or sh-nc were established by infection with corresponding lentivirus vectors. 1 x 106 mL-1 (100 uL) cells were subcutaneously inoculated into the nude mice. The tumor volumes had been measured from day 5 to day 25. On day 25, the xenograft tumors were removed surgically, and the tumor weight was detected.
Click to Show/Hide
|
||||
Response regulation | CircBCAR3 binds with miR-27a-3p to promote TNPO1 expression. GPX4 protein levels were increased by silencing of circBCAR3. And circBCAR3 promoted the proliferation, migration, invasion, and ferroptosis of esophageal cancer cells by miR-27a-3p. | ||||
Experiment 9 Reporting the Ferroptosis-centered Disease Response by This Target | [6] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70] | ||||
Responsed Regulator | hsa-miR-30a-5p (miRNA) | Driver | |||
Pathway Response | Wnt signaling pathway | hsa04310 | |||
Fatty acid metabolism | hsa01212 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
Cell invasion | |||||
In Vitro Model | EC9706 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_E307 | |
KYSE-70 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1356 | ||
hEECs (Human esophageal epithelial cells) | |||||
In Vivo Model |
BALB/c nude male mice of 4 weeks old were purchased from the Model Animal Research Center of Nanjing University (Nanjing, China). After one week of adaptive feeding, EC9706 cells (3 x 106) stably expressing sh-NC and sh-circPVT1, sh-NC + 5-FU and sh-circPVT1 + 5-FU were subcutaneously were injected into the right flank of the nude mice in a serum-free DMEM medium.
Click to Show/Hide
|
||||
Response regulation | CircPVT1 regulated the chemosensitivity of esophageal squamous cell carcinoma cells through ROS and Wnt/-catenin pathwaysvia miR-30a-5p/FZD3. Knockdown of circPVT1 promoted chemosensitivity in ESCC by increasing ferroptosis via downregulating GPX4 and SLC7A11. | ||||
Experiment 10 Reporting the Ferroptosis-centered Disease Response by This Target | [9] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Oesophageal carcinoma [ICD-11: 2B70] | ||||
Responsed Regulator | OIP5-AS1 (IncRNA) | Suppressor | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Fatty acid metabolism | hsa01212 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model | Eca-109 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_6898 | |
TE-13 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_4463 | ||
TE-1 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 | ||
T.Tn cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_3175 | ||
hOECs (Normal oesophageal epithelial cells) | |||||
Response regulation | OIP5-AS1 inhibition significantly inhibited Oesophageal cancer (EC) cell viability and proliferation, induced ferroptosis, and downregulated GPX4 levels, while GPX4 reversed these effects. | ||||
Experiment 11 Reporting the Ferroptosis-centered Disease Response by This Target | [6] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70] | ||||
Responsed Regulator | CircPVT1 (circRNA) | Suppressor | |||
Pathway Response | Wnt signaling pathway | hsa04310 | |||
Fatty acid metabolism | hsa01212 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
Cell invasion | |||||
In Vitro Model | EC9706 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_E307 | |
KYSE-70 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1356 | ||
hEECs (Human esophageal epithelial cells) | |||||
In Vivo Model |
BALB/c nude male mice of 4 weeks old were purchased from the Model Animal Research Center of Nanjing University (Nanjing, China). After one week of adaptive feeding, EC9706 cells (3 x 106) stably expressing sh-NC and sh-circPVT1, sh-NC + 5-FU and sh-circPVT1 + 5-FU were subcutaneously were injected into the right flank of the nude mice in a serum-free DMEM medium.
Click to Show/Hide
|
||||
Response regulation | CircPVT1 regulated the chemosensitivity of esophageal squamous cell carcinoma cells through ROS and Wnt/-catenin pathwaysviamiR-30a-5p/FZD3. Knockdown of circPVT1 promoted chemosensitivity in ESCC by increasing ferroptosis via downregulating GPX4 and SLC7A11. | ||||
Experiment 12 Reporting the Ferroptosis-centered Disease Response by This Target | [7] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Esophageal cancer [ICD-11: 2B70] | ||||
Responsed Regulator | CircBCAR3 (circRNA) | Driver | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
Cell migration | |||||
Cell invasion | |||||
In Vitro Model | Eca-109 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_6898 | |
In Vivo Model |
Nude mice of both sexes (age: 6-8 weeks, weight: 22-25 g) were purchased from HUNAN SJA LABRATORY ANIMAL CO., LTD (Hunan, China). The EC109 cells stably expressing sh-circBCAR3 or sh-nc were established by infection with corresponding lentivirus vectors. 1 x 106 mL-1 (100 uL) cells were subcutaneously inoculated into the nude mice. The tumor volumes had been measured from day 5 to day 25. On day 25, the xenograft tumors were removed surgically, and the tumor weight was detected.
Click to Show/Hide
|
||||
Response regulation | CircBCAR3 binds with miR-27a-3p to promote TNPO1 expression. GPX4 protein levels were increased by silencing of circBCAR3. And circBCAR3 promoted the proliferation, migration, invasion, and ferroptosis of esophageal cancer cells by miR-27a-3p. | ||||
Unspecific Target
In total 8 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [2] | ||||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70] | ||||
Responsed Drug | Allicin | Investigative | |||
Responsed Regulator | Ubiquitin-like modifier-activating enzyme ATG7 (ATG7) | Driver | |||
Pathway Response | mTOR signaling pathway | hsa04150 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell autophagy | |||||
In Vitro Model | TE-1 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 | |
KYSE-510 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1354 | ||
HET-1A cells | Normal | Homo sapiens | CVCL_3702 | ||
In Vivo Model |
All mice were housed in a specific pathogen-free environment under a standard 12 h light-dark cycle at 25 and had ad libitum access to food and water. Approximately 4 x 106 KYSE510 cells in 100 uL of normal saline were subcutaneously injected into the right flank of mice (n = 20 in total). All mice were allocated to a control or 10 mg/kg allicin group (n = 10 per group), as previously described (Suddek 2014). The mice were orally administered allicin or normal saline once daily for 28 days.
Click to Show/Hide
|
||||
Response regulation | In summary, allicin may induce cell death in esophageal squamous cell carcinoma (ESCC) cells by activating AMPK/mTOR-mediated autophagy and ferroptosis. Furthermore, ATG5 and ATG7 expression increased in tumors after allicin treatment. In contrast, NCOA4 expression increased, but the protein level of FTH1 and TfR1 decreased in tumors after allicin treatment. | ||||
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target | [2] | ||||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70] | ||||
Responsed Drug | Allicin | Investigative | |||
Responsed Regulator | Serine/threonine-protein kinase mTOR (MTOR) | Suppressor | |||
Pathway Response | mTOR signaling pathway | hsa04150 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell autophagy | |||||
In Vitro Model | TE-1 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 | |
KYSE-510 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1354 | ||
HET-1A cells | Normal | Homo sapiens | CVCL_3702 | ||
In Vivo Model |
All mice were housed in a specific pathogen-free environment under a standard 12 h light-dark cycle at 25 and had ad libitum access to food and water. Approximately 4 x 106 KYSE510 cells in 100 uL of normal saline were subcutaneously injected into the right flank of mice (n = 20 in total). All mice were allocated to a control or 10 mg/kg allicin group (n = 10 per group), as previously described (Suddek 2014). The mice were orally administered allicin or normal saline once daily for 28 days.
Click to Show/Hide
|
||||
Response regulation | In summary, allicin may induce cell death in esophageal squamous cell carcinoma (ESCC) cells by activating AMPK/mTOR-mediated autophagy and ferroptosis. Furthermore, ATG5 and ATG7 expression increased in tumors after allicin treatment. In contrast, NCOA4 expression increased, but the protein level of FTH1 and TfR1 decreased in tumors after allicin treatment. | ||||
Experiment 3 Reporting the Ferroptosis-centered Disease Response by This Target | [2] | ||||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70] | ||||
Responsed Drug | Allicin | Investigative | |||
Responsed Regulator | Autophagy protein 5 (ATG5) | Driver | |||
Pathway Response | mTOR signaling pathway | hsa04150 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell autophagy | |||||
In Vitro Model | TE-1 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 | |
KYSE-510 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1354 | ||
HET-1A cells | Normal | Homo sapiens | CVCL_3702 | ||
In Vivo Model |
All mice were housed in a specific pathogen-free environment under a standard 12 h light-dark cycle at 25 and had ad libitum access to food and water. Approximately 4 x 106 KYSE510 cells in 100 uL of normal saline were subcutaneously injected into the right flank of mice (n = 20 in total). All mice were allocated to a control or 10 mg/kg allicin group (n = 10 per group), as previously described (Suddek 2014). The mice were orally administered allicin or normal saline once daily for 28 days.
Click to Show/Hide
|
||||
Response regulation | In summary, allicin may induce cell death in esophageal squamous cell carcinoma (ESCC) cells by activating AMPK/mTOR-mediated autophagy and ferroptosis. Furthermore, ATG5 and ATG7 expression increased in tumors after allicin treatment. In contrast, NCOA4 expression increased, but the protein level of FTH1 and TfR1 decreased in tumors after allicin treatment. | ||||
Experiment 4 Reporting the Ferroptosis-centered Disease Response by This Target | [3] | ||||
Responsed Disease | Esophageal cancer [ICD-11: 2B70] | ||||
Responsed Drug | APR-246 | Investigative | |||
Responsed Regulator | Cysteine desulfurase (NFS1) | Driver | |||
Pathway Response | Glutathione metabolism | hsa00480 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model | NCI-H1299 cells | Lung large cell carcinoma | Homo sapiens | CVCL_0060 | |
OACM5.1 C cells | Esophageal adenocarcinoma | Homo sapiens | CVCL_1842 | ||
FLO-1 cells | Barrett adenocarcinoma | Homo sapiens | CVCL_2045 | ||
HEK-293T cells | Normal | Homo sapiens | CVCL_0063 | ||
In Vivo Model |
For FLO-1 LM cell line xenografts, 5 x 106 cells suspended in 100 ul of 1:1 PBS and Matrigel (BD Biosciences) were subcutaneously injected into the right flank of ~6 week-old female nonobese diabeticsevere combined immunodeficient interleukin-2RKO (NSG) mice. PDXs were established and implanted into a dorsal intramuscular pocket of NSG mice as previously described. Mice were randomized to SG deplete or control chow ad libitum (AIN93G rodent diet, Specialty Feeds, Australia) and dosed with eprenetapopt (100 mg/kg) or 0.9% saline, intraperitoneally injected daily, once tumors reached 100 mm3. Tumor volume was assessed blinded to treatment group with caliper measurements every 3 to 4 days and calculated using the formula (length x weight2)/2. Metastatic spread was determined by bioluminescence imaging as previously described involving weekly monitoring using the Xenogen IVIS 100 Imaging System (Caliper Life Science). At experimental end point (tumor volume > 1400 mm3), the whole mouse and its organs were imaged to determine the extent and distribution of metastases. Tumors were weighed and tumor growth inhibition was calculated with the formula [1 - (Tf- Ti)/mean(Cf - Ci)] x 100, where Tf, Ti, Cf, and Ci represent final (f) and initial (i) tumor volume of drug treated (T) and control (C) animals, respectively.
Click to Show/Hide
|
||||
Response regulation | The study demonstrates that eprenetapopt targets cancer cells through GSH depletion and inhibiting cysteine desulfurase activity of NFS1, leading to iron-dependent, nonapoptotic ferroptosis. The combination of eprenetapopt with dietary serine and glycine restriction synergizes to inhibit esophageal xenograft tumor growth. | ||||
Experiment 5 Reporting the Ferroptosis-centered Disease Response by This Target | [12] | ||||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70] | ||||
Responsed Regulator | LINC01004 (IncRNA) | Suppressor | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model | TE-1 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 | |
KYSE30 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1351 | ||
In Vivo Model |
A total of 128 immune active female C57BL/6 mice (6 weeks old) were procured from SLAC Laboratory Animal Co., Ltd. (Shanghai, China). ESCC cells (TE-1 and KYSE-30) resuspended in PBS were mixed with Matrigel and subcutaneously injected into the mice (1 x 106 cells per mouse) at the right flank to induce subcutaneous tumors. When the tumor size reached around 150 mm3, the tumor site was locally exposed to irradiation (2 Gy/d for consecutive 4 d). For antibody injection, the mice were injected with IgG or Anti-SIGECE on day 1, 7, or 14 after the first irradiation exposure. After 28 d, the mice were euthanized via overdosed barbiturate (150 mg/kg). The subcutaneous tumors were collected for IHC. Another group of ESCC cells were injected into mice via tail vein (2 x 106 cells per mouse).
Click to Show/Hide
|
||||
Response regulation | LINC01004 recruited Spi-1 proto-oncogene (SPI1) in nucleus of TAMs to induce transcriptional activation of SIGLEC9. SIGLEC9 interacted with mucin 1 (MUC1). MUC1 overexpression in esophageal squamous cell carcinoma (ESCC) induced M2 skewing of TAMs, enhanced radioresistance and immunosuppression, and promoted nuclear translocation of -catenin to suppress radiotherapy-induced ferroptosis of ESCC cells. | ||||
Experiment 6 Reporting the Ferroptosis-centered Disease Response by This Target | [12] | ||||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70] | ||||
Responsed Regulator | Transcription factor PU.1 (SPI1) | Suppressor | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model | TE-1 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 | |
KYSE30 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1351 | ||
In Vivo Model |
A total of 128 immune active female C57BL/6 mice (6 weeks old) were procured from SLAC Laboratory Animal Co., Ltd. (Shanghai, China). ESCC cells (TE-1 and KYSE-30) resuspended in PBS were mixed with Matrigel and subcutaneously injected into the mice (1 x 106 cells per mouse) at the right flank to induce subcutaneous tumors. When the tumor size reached around 150 mm3, the tumor site was locally exposed to irradiation (2 Gy/d for consecutive 4 d). For antibody injection, the mice were injected with IgG or Anti-SIGECE on day 1, 7, or 14 after the first irradiation exposure. After 28 d, the mice were euthanized via overdosed barbiturate (150 mg/kg). The subcutaneous tumors were collected for IHC. Another group of ESCC cells were injected into mice via tail vein (2 x 106 cells per mouse).
Click to Show/Hide
|
||||
Response regulation | LINC01004 recruited Spi-1 proto-oncogene (SPI1) in nucleus of TAMs to induce transcriptional activation of SIGLEC9. SIGLEC9 interacted with mucin 1 (MUC1). MUC1 overexpression in esophageal squamous cell carcinoma (ESCC) induced M2 skewing of TAMs, enhanced radioresistance and immunosuppression, and promoted nuclear translocation of -catenin to suppress radiotherapy-induced ferroptosis of ESCC cells. | ||||
Experiment 7 Reporting the Ferroptosis-centered Disease Response by This Target | [12] | ||||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70] | ||||
Responsed Regulator | Sialic acid-binding Ig-like lectin 9 (SIGLEC9) | Suppressor | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model | TE-1 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 | |
KYSE30 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1351 | ||
In Vivo Model |
A total of 128 immune active female C57BL/6 mice (6 weeks old) were procured from SLAC Laboratory Animal Co., Ltd. (Shanghai, China). ESCC cells (TE-1 and KYSE-30) resuspended in PBS were mixed with Matrigel and subcutaneously injected into the mice (1 x 106 cells per mouse) at the right flank to induce subcutaneous tumors. When the tumor size reached around 150 mm3, the tumor site was locally exposed to irradiation (2 Gy/d for consecutive 4 d). For antibody injection, the mice were injected with IgG or Anti-SIGECE on day 1, 7, or 14 after the first irradiation exposure. After 28 d, the mice were euthanized via overdosed barbiturate (150 mg/kg). The subcutaneous tumors were collected for IHC. Another group of ESCC cells were injected into mice via tail vein (2 x 106 cells per mouse).
Click to Show/Hide
|
||||
Response regulation | LINC01004 recruited Spi-1 proto-oncogene (SPI1) in nucleus of TAMs to induce transcriptional activation of SIGLEC9. SIGLEC9 interacted with mucin 1 (MUC1). MUC1 overexpression in esophageal squamous cell carcinoma (ESCC) induced M2 skewing of TAMs, enhanced radioresistance and immunosuppression, and promoted nuclear translocation of -catenin to suppress radiotherapy-induced ferroptosis of ESCC cells. | ||||
Experiment 8 Reporting the Ferroptosis-centered Disease Response by This Target | [12] | ||||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70] | ||||
Responsed Regulator | Mucin-1 (MUC1) | Suppressor | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model | TE-1 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 | |
KYSE30 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1351 | ||
In Vivo Model |
A total of 128 immune active female C57BL/6 mice (6 weeks old) were procured from SLAC Laboratory Animal Co., Ltd. (Shanghai, China). ESCC cells (TE-1 and KYSE-30) resuspended in PBS were mixed with Matrigel and subcutaneously injected into the mice (1 x 106 cells per mouse) at the right flank to induce subcutaneous tumors. When the tumor size reached around 150 mm3, the tumor site was locally exposed to irradiation (2 Gy/d for consecutive 4 d). For antibody injection, the mice were injected with IgG or Anti-SIGECE on day 1, 7, or 14 after the first irradiation exposure. After 28 d, the mice were euthanized via overdosed barbiturate (150 mg/kg). The subcutaneous tumors were collected for IHC. Another group of ESCC cells were injected into mice via tail vein (2 x 106 cells per mouse).
Click to Show/Hide
|
||||
Response regulation | LINC01004 recruited Spi-1 proto-oncogene (SPI1) in nucleus of TAMs to induce transcriptional activation of SIGLEC9. SIGLEC9 interacted with mucin 1 (MUC1). MUC1 overexpression in esophageal squamous cell carcinoma (ESCC) induced M2 skewing of TAMs, enhanced radioresistance and immunosuppression, and promoted nuclear translocation of -catenin to suppress radiotherapy-induced ferroptosis of ESCC cells. | ||||
Nuclear receptor coactivator 4 (NCOA4)
In total 1 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [2] | ||||
Target for Ferroptosis | Driver | ||||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70] | ||||
Responsed Drug | Allicin | Investigative | |||
Pathway Response | mTOR signaling pathway | hsa04150 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell autophagy | |||||
In Vitro Model | TE-1 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 | |
KYSE-510 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1354 | ||
HET-1A cells | Normal | Homo sapiens | CVCL_3702 | ||
In Vivo Model |
All mice were housed in a specific pathogen-free environment under a standard 12 h light-dark cycle at 25 and had ad libitum access to food and water. Approximately 4 x 106 KYSE510 cells in 100 uL of normal saline were subcutaneously injected into the right flank of mice (n = 20 in total). All mice were allocated to a control or 10 mg/kg allicin group (n = 10 per group), as previously described (Suddek 2014). The mice were orally administered allicin or normal saline once daily for 28 days.
Click to Show/Hide
|
||||
Response regulation | In summary, allicin may induce cell death in esophageal squamous cell carcinoma (ESCC) cells by activating AMPK/mTOR-mediated autophagy and ferroptosis. Furthermore, ATG5 and ATG7 expression increased in tumors after allicin treatment. In contrast, NCOA4 expression increased, but the protein level of FTH1 and TfR1 decreased in tumors after allicin treatment. | ||||
Heme oxygenase 1 (HMOX1)
In total 1 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [4] | ||||
Target for Ferroptosis | Driver/Suppressor | ||||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70] | ||||
Responsed Drug | 5-aminolevulinic acid | Approved | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model | KYSE30 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1351 | |
KYSE-510 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1354 | ||
MKN45 cells | Gastric adenocarcinoma | Homo sapiens | CVCL_0434 | ||
In Vivo Model |
KYSE30 cells were subcutaneously inoculated with 5 x 106 cells per site into both flanks on day 0. At 1 week after transplantation, tumor-bearing mice were randomly assigned to one of the following three groups: (1) saline as a control, (2) 10 mg/kg/day of 5-ALA, or (3) 30 mg/kg/day of 5-ALA. The treatment groups were orally administered 5-ALA once daily for 4 weeks, and the control group was orally administered saline during the same period.
Click to Show/Hide
|
||||
Response regulation | Modulation of GPX4 and HMOX1 by 5-aminolevulinic acid (5-ALA) induced ferroptosis in esophageal squamous cell carcinoma (ESCC). Furthermore, 5-ALA led to an increase in lipid peroxidation and exerted an antitumor effect in various cancer cell lines, which was inhibited by ferrostatin-1. Thus, 5-ALA could be a promising new therapeutic agent for ESCC. | ||||
Cystine/glutamate transporter (SLC7A11)
In total 8 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [10] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70] | ||||
Responsed Regulator | Disintegrin and metalloproteinase domain-containing protein 23 (ADAM23) | Driver | |||
Pathway Response | Glutathione metabolism | hsa00480 | |||
Fatty acid metabolism | hsa01212 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
Cell migration | |||||
In Vitro Model | EC9706 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_E307 | |
TE-1 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 | ||
Eca-109 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_6898 | ||
HET-1A cells | Normal | Homo sapiens | CVCL_3702 | ||
Response regulation | ARHGEF26-AS1 facilitated ferroptosis but restrained cell growth and positively regulated ADAM23 by sponging miR-372-3p in esophageal squamous cell carcinoma (ESCC). Overexpression of ARHGEF26-AS1 upregulated the protein levels of ADAM23 but depleted the protein levels of GPX4, 3SLC3A2, and SLC7A11. | ||||
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target | [6] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70] | ||||
Responsed Regulator | Frizzled-3 (FZD3) | Suppressor | |||
Pathway Response | Wnt signaling pathway | hsa04310 | |||
Fatty acid metabolism | hsa01212 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
Cell invasion | |||||
In Vitro Model | EC9706 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_E307 | |
KYSE-70 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1356 | ||
hEECs (Human esophageal epithelial cells) | |||||
In Vivo Model |
BALB/c nude male mice of 4 weeks old were purchased from the Model Animal Research Center of Nanjing University (Nanjing, China). After one week of adaptive feeding, EC9706 cells (3 x 106) stably expressing sh-NC and sh-circPVT1, sh-NC + 5-FU and sh-circPVT1 + 5-FU were subcutaneously were injected into the right flank of the nude mice in a serum-free DMEM medium.
Click to Show/Hide
|
||||
Response regulation | CircPVT1 regulated the chemosensitivity of esophageal squamous cell carcinoma cells through ROS and Wnt/-catenin pathwaysviamiR-30a-5p/FZD3. Knockdown of circPVT1 promoted chemosensitivity in ESCC by increasing ferroptosis via downregulating GPX4 and SLC7A11. | ||||
Experiment 3 Reporting the Ferroptosis-centered Disease Response by This Target | [6] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70] | ||||
Responsed Regulator | hsa-miR-30a-5p (miRNA) | Driver | |||
Pathway Response | Wnt signaling pathway | hsa04310 | |||
Fatty acid metabolism | hsa01212 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
Cell invasion | |||||
In Vitro Model | EC9706 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_E307 | |
KYSE-70 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1356 | ||
hEECs (Human esophageal epithelial cells) | |||||
In Vivo Model |
BALB/c nude male mice of 4 weeks old were purchased from the Model Animal Research Center of Nanjing University (Nanjing, China). After one week of adaptive feeding, EC9706 cells (3 x 106) stably expressing sh-NC and sh-circPVT1, sh-NC + 5-FU and sh-circPVT1 + 5-FU were subcutaneously were injected into the right flank of the nude mice in a serum-free DMEM medium.
Click to Show/Hide
|
||||
Response regulation | CircPVT1 regulated the chemosensitivity of esophageal squamous cell carcinoma cells through ROS and Wnt/-catenin pathways via miR-30a-5p/FZD3. Knockdown of circPVT1 promoted chemosensitivity in ESCC by increasing ferroptosis via downregulating GPX4 and SLC7A11. | ||||
Experiment 4 Reporting the Ferroptosis-centered Disease Response by This Target | [10] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70] | ||||
Responsed Regulator | hsa-miR-372-3p (miRNA) | Suppressor | |||
Pathway Response | Glutathione metabolism | hsa00480 | |||
Fatty acid metabolism | hsa01212 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
Cell migration | |||||
In Vitro Model | EC9706 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_E307 | |
TE-1 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 | ||
Eca-109 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_6898 | ||
HET-1A cells | Normal | Homo sapiens | CVCL_3702 | ||
Response regulation | ARHGEF26-AS1 facilitated ferroptosis but restrained cell growth and positively regulated ADAM23 by sponging miR-372-3p in esophageal squamous cell carcinoma (ESCC). Overexpression of ARHGEF26-AS1 upregulated the protein levels of ADAM23 but depleted the protein levels of GPX4, SLC3A2, and SLC7A11. | ||||
Experiment 5 Reporting the Ferroptosis-centered Disease Response by This Target | [11] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70] | ||||
Responsed Regulator | hsa-miR-513a-3p (miRNA) | Driver | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Cell Process | Cell ferroptosis | ||||
Cell apoptosis | |||||
Cell proliferation | |||||
In Vitro Model | hESCCs (Esophageal squamous cancer cells) | ||||
Response regulation | Downregulation of BBOX1-AS1 inhibits cell proliferation, and metastasis accelerates cell apoptosis and ferroptosis in esophageal squamous cell cancer by upregulating miR-513a-3p to reduce SLC7A11 expression. These findings may provide novel insights into the diagnosis and treatment of ESCC. | ||||
Experiment 6 Reporting the Ferroptosis-centered Disease Response by This Target | [10] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70] | ||||
Responsed Regulator | ARHGEF26-AS1 (IncRNA) | Driver | |||
Pathway Response | Glutathione metabolism | hsa00480 | |||
Fatty acid metabolism | hsa01212 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
Cell migration | |||||
In Vitro Model | EC9706 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_E307 | |
TE-1 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 | ||
Eca-109 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_6898 | ||
HET-1A cells | Normal | Homo sapiens | CVCL_3702 | ||
Response regulation | ARHGEF26-AS1 facilitated ferroptosis but restrained cell growth and positively regulated ADAM23 by sponging miR-372-3p in esophageal squamous cell carcinoma (ESCC). Overexpression of ARHGEF26-AS1 upregulated the protein levels of ADAM23 but depleted the protein levels of GPX4, SLC3A2, and SLC7A11. | ||||
Experiment 7 Reporting the Ferroptosis-centered Disease Response by This Target | [11] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70] | ||||
Responsed Regulator | BBOX1-AS1 (IncRNA) | Suppressor | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Cell Process | Cell ferroptosis | ||||
Cell apoptosis | |||||
Cell proliferation | |||||
In Vitro Model | hESCCs (Esophageal squamous cancer cells) | ||||
Response regulation | Downregulation of BBOX1-AS1 inhibits cell proliferation, and metastasis accelerates cell apoptosis and ferroptosis in esophageal squamous cell cancer by upregulating miR-513a-3p to reduce SLC7A11 expression. These findings may provide novel insights into the diagnosis and treatment of ESCC. | ||||
Experiment 8 Reporting the Ferroptosis-centered Disease Response by This Target | [6] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70] | ||||
Responsed Regulator | CircPVT1 (circRNA) | Suppressor | |||
Pathway Response | Wnt signaling pathway | hsa04310 | |||
Fatty acid metabolism | hsa01212 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
Cell invasion | |||||
In Vitro Model | EC9706 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_E307 | |
KYSE-70 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1356 | ||
hEECs (Human esophageal epithelial cells) | |||||
In Vivo Model |
BALB/c nude male mice of 4 weeks old were purchased from the Model Animal Research Center of Nanjing University (Nanjing, China). After one week of adaptive feeding, EC9706 cells (3 x 106) stably expressing sh-NC and sh-circPVT1, sh-NC + 5-FU and sh-circPVT1 + 5-FU were subcutaneously were injected into the right flank of the nude mice in a serum-free DMEM medium.
Click to Show/Hide
|
||||
Response regulation | CircPVT1 regulated the chemosensitivity of esophageal squamous cell carcinoma cells through ROS and Wnt/-catenin pathwaysviamiR-30a-5p/FZD3. Knockdown of circPVT1 promoted chemosensitivity in ESCC by increasing ferroptosis via downregulating GPX4 and SLC7A11. | ||||
4F2 cell-surface antigen heavy chain (SLC3A2)
In total 3 item(s) under this target | ||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [10] | |||
Target for Ferroptosis | Suppressor | |||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70] | |||
Responsed Regulator | Disintegrin and metalloproteinase domain-containing protein 23 (ADAM23) | Driver | ||
Pathway Response | Glutathione metabolism | hsa00480 | ||
Fatty acid metabolism | hsa01212 | |||
Cell Process | Cell ferroptosis | |||
Cell proliferation | ||||
Cell migration | ||||
In Vitro Model | EC9706 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_E307 |
TE-1 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 | |
Eca-109 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_6898 | |
HET-1A cells | Normal | Homo sapiens | CVCL_3702 | |
Response regulation | ARHGEF26-AS1 facilitated ferroptosis but restrained cell growth and positively regulated ADAM23 by sponging miR-372-3p in esophageal squamous cell carcinoma (ESCC). Overexpression of ARHGEF26-AS1 upregulated the protein levels of ADAM23 but depleted the protein levels of GPX4, SLC3A2, and SLC7A11. | |||
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target | [10] | |||
Target for Ferroptosis | Suppressor | |||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70] | |||
Responsed Regulator | hsa-miR-372-3p (miRNA) | Suppressor | ||
Pathway Response | Glutathione metabolism | hsa00480 | ||
Fatty acid metabolism | hsa01212 | |||
Cell Process | Cell ferroptosis | |||
Cell proliferation | ||||
Cell migration | ||||
In Vitro Model | EC9706 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_E307 |
TE-1 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 | |
Eca-109 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_6898 | |
HET-1A cells | Normal | Homo sapiens | CVCL_3702 | |
Response regulation | ARHGEF26-AS1 facilitated ferroptosis but restrained cell growth and positively regulated ADAM23 by sponging miR-372-3p in esophageal squamous cell carcinoma (ESCC). Overexpression of ARHGEF26-AS1 upregulated the protein levels of ADAM23 but depleted the protein levels of GPX4, SLC3A2, and SLC7A11. | |||
Experiment 3 Reporting the Ferroptosis-centered Disease Response by This Target | [10] | |||
Target for Ferroptosis | Suppressor | |||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70] | |||
Responsed Regulator | ARHGEF26-AS1 (IncRNA) | Driver | ||
Pathway Response | Glutathione metabolism | hsa00480 | ||
Fatty acid metabolism | hsa01212 | |||
Cell Process | Cell ferroptosis | |||
Cell proliferation | ||||
Cell migration | ||||
In Vitro Model | EC9706 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_E307 |
TE-1 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 | |
Eca-109 cells | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_6898 | |
HET-1A cells | Normal | Homo sapiens | CVCL_3702 | |
Response regulation | ARHGEF26-AS1 facilitated ferroptosis but restrained cell growth and positively regulated ADAM23 by sponging miR-372-3p in esophageal squamous cell carcinoma (ESCC). Overexpression of ARHGEF26-AS1 upregulated the protein levels of ADAM23 but depleted the protein levels of GPX4, SLC3A2, and SLC7A11. | |||
References